FlexiOss® Ortho
Third-generation flexible bone substitute with TriCurean biphasic formula for orthopedic and traumatology procedures.
Modern implantable biomaterial — biphasic (hydroxyapatite-polymeric), bioactive, supporting bone tissue regeneration and a potential drug carrier. After implantation, it integrates with patient's bone and is slowly remodelled into natural bone tissue, eliminating reoperation.
Product Demonstration
FlexiOss® Ortho — Orthopedic Applications
Discover how FlexiOss® Ortho revolutionizes trauma and orthopedic surgery. See the flexible, moldable properties that allow surgeons to customize the implant during operation for optimal bone regeneration.
What Makes FlexiOss® Ortho Unique
Flexible After Soaking
Plastic and bendable — fits individual bone defects by cutting or bending during operation
Bio-Compatible
Compatible with natural bone tissue for seamless integration
Mechanical Parameters
Similar to those of cancellous bone — structural support
Supports Bone Reconstruction
Actively supports the bone reconstruction process
Absorbs Blood & Medicine
Absorbs blood and medicine solutions for enhanced drug delivery
Bone Tissue Regeneration
Positively affects bone tissue regeneration process
Ionic Reactive / Bioactive
High ionic reactivity increases mineralization rate
Non-Toxic Material
Thoroughly tested for safety — no cytotoxicity observed
Up to 7cm Defects
Can be used for bone defects of up to 7 cm in length
Non-Animal Material
Lowers risk of pathogen transmission and allergic reactions
Easy to Store & Transport
Simple storage and transportation requirements
Biphasic Formula
The combination of two main compounds was obtained by polymer gelling into an irreversible, collagen-like triple helix — a conformation which does not evoke local inflammation and enables the entrapment of HAP granulate.
Hydroxyapatite (HAP)
- Low-sintered, highly porous ceramic
- Fully synthetic — high chemical stability
- Supports regeneration via enhanced ion uptake
- Most stable form of calcium phosphate
Curdlan Polymer
- Triple-helix structure (collagen-like)
- Neutral for macrophages — no inflammation
- Enables flexibility and high absorbency
- Provides form stability
Clinical Applications
- Comminuted fractures with bone tissue defects
- Long bone defect filling and reconstruction (up to 5-7 cm)
- Trauma surgery and emergency medicine
- Bone pocket filling for tissue regeneration
- Post-infective cyst removal and filling
- Bone tumour resection defect reconstruction
- Osteoporotic bone tissue fracture therapy
- Bioactive filling of titanium and polyester scaffolds
- Spinal fusion augmentation
- Joint revision and arthrodesis procedures
Orthopaedics
Primary application area
Musculoskeletal Trauma
Emergency & reconstructive
Dentistry
Cyst & fistulae treatment
Veterinary
Companion animals
Certifications & Patents
CE Certified
EC Certificate No. 1434-MDD-269/2021
European conformity — highest safety standards
PH-FDA Approved
CMDR-2025-04943A
Certified for orthopedic applications in the Philippines
Patent Protected
European Patents
Protected in England, Austria, France, Spain, Ireland, Germany, Poland, Italy
FlexiOss® vs Competitors
| Feature | FlexiOss® Ortho | Bio-Oss® (Geistlich) | Infuse® BMP-2 |
|---|---|---|---|
| Flexibility | Flexible & moldable after soaking | Rigid granules | Collagen sponge — limited shape |
| Can Be Milled | Yes — personalized implant | No | No |
| Origin | Fully synthetic (non-animal) | Bovine bone (animal) | Recombinant protein |
| Drug Carrier | Antibiotics, PRP, growth factors | Limited absorption | BMP-2 only |
| Contamination Risk | Minimal (synthetic) | Prion/virus risk (bovine) | Low but complex production |
| Healing Time | 50% faster than standard | Standard healing rate | Fast but with swelling risk |
| Haemostatic | Yes — reduces bleeding | No | No |
| Reoperation Needed | No — remodels naturally | Slow resorption | No |
| Cost | Competitive | Premium | Very expensive |
Published Research
Characteristics and application of FlexiOss® bone substitute material in trauma-orthopedic patients
Lukasiewicz P.
Preliminary Results of Surgical Treatment for Enchondroma Using a Novel Bioactive and Osseoconductive HAP/β-Glucan Bone Substitute FlexiOss® — Case Series
Kotrych D., Ciechanowicz D., Bielewicz F., Baryluk A., Podsiadlo S., Zietek P.
Behavior of new hydroxyapatite/glucan composite in human serum
Borkowski L., Lubek T., Jojczuk M., Nogalski A., Belcarz A., Palka K., Hajnos M., Ginalska G.
Unexpected reaction of new HAp/glucan composite to environmental acidification: Defect or advantage?
Borkowski L., Kiernicka M., Belcarz A., Palka K., Hajnos M., Ginalska G.
The comparison study of bioactivity between composites containing synthetic non-substituted and carbonate-substituted hydroxyapatite
Borkowski L., Sroka-Bartnicka A., et al.
Biphasic mode of antibacterial action of aminoglycoside antibiotics-loaded elastic hydroxyapatite-glucan composite
Belcarz A., Zima A., Ginalska G.
Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair
Belcarz A., Ginalska G., Pycka T., et al.